GLYC - GlycoMimetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240-243-1201
http://www.glycomimetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Mrs. Rachel K. KingCEO & Director772.42kN/A1959
Mr. Brian M. HahnCFO & Sec.458.38kN/A1974
Dr. John L. Magnani Ph.D.Sr. VP of Research, Chief Scientific Officer & Director529.58kN/A1953
Dr. Helen M. Thackray M.D., FAAPSr. VP of Clinical Devel. & Chief Medical Officer577.27kN/A1968
Mr. Henry FlannerVP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Corporate Governance

GlycoMimetics, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.